Handling BPC-157 and TB-500 stocks in parallel — labelling discipline

Bench-logistics question, not a stacking question. When I'm working with BPC-157 and TB-500 reconstituted stocks side by side, the two clear solutions look identical in the rack. I nearly pipetted from the wrong one last week.

How do you keep parallel stocks visually distinct? Coloured cap dots? Different rack rows? Curious what's worked for people running more than one compound at the bench.

Coloured cap dots, different rack rows, AND the compound abbreviation on the cap. Three signals because two clear liquids in identical vials is exactly how a mix-up happens.

I never have two reconstituted stocks open on the bench at once. One comes out, gets used, goes back, then the other. Slower, but I've never grabbed the wrong vial.

Both of these are better than my colour-dots-only system. Combining them: one stock out at a time AND distinct cap markings as backup. Updating my SOP, thank you.

Want to join the discussion?

Related discussions

Ipamorelin handling + appearance notes wanted

Recording concentration on the vial label (not a dosing question)

GHK-Cu solution is blue — that is expected, right?

MOTS-c solubility notes — anyone documented theirs?

Reading purity on a newer compound like Retatrutide

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research